Buy Score Rank #3664 out of #5176
Wed 26'th Jul 2017
Proteon Therapeutics Stock Analysis
Technical stock analysis for Wed 26'th Jul 2017
Sell candidate since 2017-07-24 Loss -3.57%
Given the current horizontal trend you can expect Proteon Therapeutics with 90% probability to be traded between $1.19 and $1.65 at the end of this period with 90% probability. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the roof. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.
There are mixed signals in the stock today. Proteon Therapeutics holds sales signals from both short- and long-term moving averages. On corrections up there will be some resistance from the lines at $1.37 and $1.36. A break-up above any of these levels will issue buy signals. Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued. A buy signal was issued from a pivot bottom point on Tuesday July 25, 2017, which indicates further gains until a new top pivot has been found.
Relative Strength Index (RSI)
RSI14 is 36 and the stock is currently not being overbought or oversold
Support & Resistance
Proteon Therapeutics finds support from accumulated volume at . On the upside the stock meets some resistance from accumulated volume at $1.60, $1.45 and $1.40.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.05 between high and low, or 3.70%. For the last week the stock has had a daily average volatility of 4.50%.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Proteon Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.